Hengrui Presents 64 Oncology Research Findings at ESMO Congress 2026
Chinese pharmaceutical firm Hengrui detailed 64 oncology research projects at the ESMO Congress in Madrid, marking a push to expand its clinical influence beyond domestic markets.
At the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Hengrui showcased data from 64 oncology research projects. The presentation focused on the company's current development pipeline and clinical trial results, underscoring its shift toward establishing a more prominent role in international cancer research.
The research covered a broad range of therapeutic areas, reflecting Hengrui’s investment in oncological treatments. By sharing these findings at a major global medical conference, the company aims to improve its visibility among international regulatory bodies and global medical practitioners.
Historically, Hengrui has been anchored in the Chinese pharmaceutical market, but the scale of its participation at ESMO signals an intent to integrate its R&D output into the global clinical landscape. The company continues to prioritize the validation of its proprietary compounds through multi-center clinical trials.